“In a clinically representative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change clinical management for substantially more patients than does BRCA1/2 testing alone. Multigene testing in this setting is likely to alter near-term cancer risk assessment and

frothmouthfrothmouth のブックマーク 2015/08/30 13:56

その他

このブックマークにはスターがありません。
最初のスターをつけてみよう!

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment - PubMed

    The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The htt...

    \ コメントが サクサク読める アプリです /

    • App Storeからダウンロード
    • Google Playで手に入れよう